Novogene to Power Cancer, Rare Disease, and Environmental Research with PacBio Sequencing

Core Insights - Novogene has established a new lab at the Innovation and Start-Up Center for Biotechnology (IZB) in Munich, which will serve as a strategic hub for its European operations and enhance its global network of labs [1] - The Revio long-read sequencing system from PacBio will complement Novogene's existing sequencing portfolio, addressing limitations in depth and accuracy that other technologies face [1][8] - There is anticipated high demand for the Revio in rare disease and cancer research, as well as in microbial and agrigenomics, enabling the assembly of full genomes of rarely studied species [1][5] Company Overview - Novogene is a leading provider of genomic services and bioinformatics expertise, with nearly 2,000 employees and a strong presence in the global market [11] - The company has a significant sequencing capacity and has been involved in over 22,000 publications in top-tier journals, establishing itself as a trusted partner in genomics [11] - Novogene utilizes advanced platforms from Illumina, PacBio, and Oxford Nanopore Technology to support its services [11] Technology and Applications - The Revio system is designed to provide high accuracy and throughput, enabling cost-effective in-depth genomic research across various fields, including rare diseases, cancer, microbes, and agriculture [8] - The Revio's capabilities allow for the identification of complex repetitive regions, structural variants, and novel isoforms that are often missed by traditional short-read and exome methods [5] - The integration of automation into Revio's workflows is planned to enhance efficiency and accessibility for a broader range of customers [5]